Johnson & Johnson announced new two-year data from a Phase 2/3 study showing that IMAAVY (nipocalimab) provides sustained disease control, improved muscle strength, and reduced corticosteroid use in adolescents with generalized myasthenia gravis (gMG). The findings also highlight that fluctuating symptoms often lead patients to switch therapies, with many improving after transitioning to IMAAVY. This treatment is the only FcRn blocker approved for pediatric patients 12 years and older with antibody-positive gMG, offering a promising option for long-term management. Further data will be presented at upcoming scientific meetings in 2026.
Following Johnson & Johnson's announcement of promising new data on IMAAVY for generalized myasthenia gravis, the company's stock shows a slight dip of 0.09% on Pluang as of Sep 29, 2026, 19:23 WIB. JNJ shares trade at USD 271.70, close to their 52-week high of USD 278.43, with a market cap of $655.37 billion. Despite the recent news, Pluang order activity leans heavily towards selling at 86%, reflecting cautious investor sentiment.
Johnson & Johnson is poised for growth with a strong oncology and immunology pipeline, including promising drugs like CARVYKTI and TREMFYA showing significant progress. The company reported a 56% stock rally over the past year and raised earnings gui...
Procter & Gamble, Johnson & Johnson, and Coca-Cola have each increased their dividends annually through eight major economic downturns since the 1960s, including stagflation, recessions, and the pandemic. These companies have strong cash flows and so...
AbbVie and Johnson & Johnson are both strong dividend stocks trading near their 52-week highs, but they differ significantly in risk and growth. AbbVie shows faster revenue growth and a higher dividend yield, driven by its immunology drugs, but faces...
Johnson & Johnson announced that its drug Tremfya significantly improved spinal pain and stiffness in adults with axial psoriatic arthritis in a Phase 4 clinical trial. The STAR study showed Tremfya outperformed placebo in reducing disease activity a...
Johnson & Johnson announced that TREMFYA (guselkumab) met primary and major secondary endpoints in the Phase 4 STAR study, showing significant improvement in axial symptoms and MRI-confirmed inflammation in biologic-naïve adults with active psoriatic...
